Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations
Open Access
- 27 April 2024
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (4) , 603-611
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation
- Gilead Sciences
This publication has 81 references indexed in Scilit:
- International consensus recommendations for the use of prolonged‐infusion beta‐lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases PharmacistsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosisPediatric Pulmonology, 2023
- The Impact of COVID-19 in Cystic FibrosisArchivos de Bronconeumología, 2021
- Comparison of Functional Free-Breathing Pulmonary 1H and Hyperpolarized 129Xe Magnetic Resonance Imaging in Pediatric Cystic FibrosisAcademic Radiology, 2021
- Evaluation of rescue oral glucocorticoid therapy during inpatient cystic fibrosis exacerbationsPediatric Pulmonology, 2020
- Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centersPediatric Pulmonology, 2020
- Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosisPediatric Pulmonology, 2012
- Approach to treating cystic fibrosis pulmonary exacerbations varies widely across us CF care centersPediatric Pulmonology, 2011
- Return of FEV1 after pulmonary exacerbation in children with cystic fibrosisPediatric Pulmonology, 2010
- Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosisPediatric Pulmonology, 2006